Skip to content
World of Video Gaming – Lifestyle
Author:
Theolytics
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events
September 16, 2026
Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies
July 16, 2026
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
May 28, 2026
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
April 28, 2026